Advancing Science. Improving Connections.

Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.

Our Patients

Focusing on the unmet medical needs of patients with rare disorders and their families

More

Our Company

Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases

More

Our Pipeline

Pioneering cannabinoid treatments for neuropsychiatric conditions

More

Latest News

09.26

Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

Read More
09.18

Zynerba Pharmaceuticals Announces Positive Top Line Data from BELIEVE 1 Open Label Phase 2 Study of Zygel™ in Developmental and Epileptic Encephalopathies (DEE)

Read More
09.05

Autism Spectrum Disorder, Fragile X Syndrome, and 22q11.2 Deletion Syndrome Share a Constellation of Sociobehavioral Symptoms

Read More
09.05

New Caregiver-Reported Data Further Validate the Use of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) Subscales to Assess Core Behavioral Symptoms of Fragile X Syndrome (FXS)

Read More

This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our Privacy Notice.